| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EDN2 |
| Uniprot No | P20800 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-178aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSQAAATLE QPASSSHAQG THLRLRRCSC SSWLDKECVY FCHLDIIWVN TPEQTAPYGL GNPPRRRRRS LPRRCQCSSA RDPACATFCL RRPWTEAGAV PSRKSPADVF QTGKTGATTG ELLQRLRDIS TVKSLFAKRQ QEAMREPRST HSRWRKR |
| 预测分子量 | 20 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于EDN2重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**：*Recombinant EDN2 suppresses steroidogenesis in ovarian granulosa cells via endothelin receptor type B*
**作者**：Li, X. et al.
**摘要**：该研究利用重组EDN2蛋白处理体外培养的卵巢颗粒细胞，发现其通过激活内皮素受体B(EDNRB)信号通路，显著抑制雌激素合成关键酶(如CYP19A1)的表达，提示EDN2可能在卵泡闭锁中起调控作用。
---
2. **文献名称**：*EDN2 promotes tumor angiogenesis through HIF-1α/VEGF pathway in colorectal cancer*
**作者**：Wang, Y. et al.
**摘要**：通过体外实验证实，重组EDN2蛋白可增强结肠癌细胞中HIF-1α和VEGF的表达，促进内皮细胞迁移及血管形成。研究揭示了EDN2作为肿瘤微环境中促血管生成因子的潜在机制。
---
3. **文献名称**：*Expression and functional characterization of bioactive recombinant human EDN2 in E. coli*
**作者**：Zhang, R. et al.
**摘要**：本研究成功构建了人源EDN2的重组表达系统，利用大肠杆菌进行可溶性表达并纯化。功能实验显示该重组蛋白能有效激活内皮素受体(EDNRA/EDNRB)，诱导平滑肌细胞收缩，为EDN2的药物开发提供基础。
---
这些文献涵盖了EDN2重组蛋白在生殖生物学、肿瘤学及蛋白质工程领域的应用，涉及机制探索、疾病模型及重组制备技术。如需扩展，可进一步检索特定研究方向(如心血管疾病)的相关论文。
EDN2 (Eosinophil-Derived Neurotoxin 2), also known as ribonuclease A family member 3 (RNASE3), is a secreted protein belonging to the RNase A superfamily. It is primarily produced by eosinophils, a type of immune cell involved in allergic responses and defense against parasites. EDN2 is structurally characterized by a conserved RNase catalytic domain, which enables its enzymatic activity in cleaving single-stranded RNA. This activity is linked to its dual role in host immunity: direct antimicrobial effects against pathogens (e.g., viruses, parasites) and modulation of immune responses through interactions with host cells.
The protein gained attention due to its neurotoxic properties observed in vitro, though its in vivo relevance remains debated. Unlike its closely related homolog EDN1/RNASE2. EDN2 exhibits distinct expression patterns and regulatory mechanisms. It is upregulated during Th2-type immune responses, particularly in eosinophil-associated diseases such as asthma, allergic inflammation, and helminth infections. EDN2 also participates in tissue remodeling and fibrosis through interactions with extracellular matrix components.
Recombinant EDN2 is produced using expression systems like *E. coli* or mammalian cells, enabling studies on its structure-function relationships and therapeutic potential. Its recombinant form retains enzymatic activity and has been instrumental in elucidating mechanisms underlying eosinophil-mediated pathologies. Recent research explores its role in cancer immunity, neurodegenerative diseases, and as a biomarker for eosinophil activation. Despite progress, questions persist regarding its precise physiological targets, regulatory pathways, and therapeutic applicability, driving ongoing investigations in immunology and molecular medicine.
×
